Advocacy Update – Oct 2024: FDA AdComm Brings Good News, Plus DC End of Year Business
FDA Advisory Committee Deems Potential Barth Syndrome Drug “Effective” Earlier this month, an FDA Advisory Committee voted 10-6...
Read moreFDA Advisory Committee Deems Potential Barth Syndrome Drug “Effective” Earlier this month, an FDA Advisory Committee voted 10-6...
Read moreAfter a full day of testimony that consistently demonstrated the need and efficacy of elamipretide for the treatment of Barth Syndrome, an FDA...
Read moreRead UMDF’s Comment to FDA’s Advisory Committee regarding New Drug Application for Elamipretide in Barth...
Read moreThe United Mitochondrial Disease Foundation today announced a new $100,000 grant to Madhurima Saha, PhD, of the University of Florida, for...
Read moreUMDF Co-Signs Letter Supporting Rare Pediatric Disease Priority Review Voucher...
Read moreThis coming week, September 16 – 22, 2024, marks World Mitochondrial Disease Week. For me, the week is deeply personal. This year marks twenty...
Read moreOn the heels of our traditional research grant funding cycle culminating at UMDF’s annual Mitochondrial Medicine conference this past June, the...
Read moreIn a few weeks, we’ll join other mitochondrial disease-focused patient advocacy groups across the globe in marking World Mitochondrial Disease...
Read moreUMDF Issues Response to Congressional 21st Century Cures Act RFI DOWNLOAD this document (PDF)...
Read more